Using social networks to recruit an hiv vaccine preparedness cohort

Journal of Acquired Immune Deficiency Syndromes

Volumn 52, Issue 4, 2009, Pages 514-523

  Valente, Thomas W ^a   Zogg, Jennifer B ^a   Christensen, Shawna ^a   Richardson, Jean ^a   Kovacs, Andrea ^a   Operskalski, Eva ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

HIV vaccine preparedness; HIV vaccines; Social networks

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; AWARENESS; CHILD; COHORT ANALYSIS; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SELF DISCLOSURE; SEXUAL BEHAVIOR; SOCIAL NETWORK;

ADOLESCENT; ADULT; AIDS VACCINES; CHILD; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; PATIENT SELECTION; PROSPECTIVE STUDIES; SOCIAL SUPPORT; YOUNG ADULT;

EID: 74049107730     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181acff91     Document Type: Article

References (41)

1. Coletti AS, Heagerty P, Sheon AR, et al. Randomized, controlled evaluation of a prototype informed consent process for HIV vaccine efficacy trials. J Acquir Immune Defic Syndr. 2003;32:161-169.
2. Brown-Peterside P, Chiasson MA, Ren L, et al. Involving women in HIV vaccine efficacy trials: lessons learned from a vaccine preparedness study in New York City. J Urban Health. 2000;77:425-437.
3. Buchbinder SP, Metch B, Holte SE, et al. Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr. 2004;36:604-612.
4. Bekker LG, Jaspan H, McIntyre J, et al. Adolescents and HIV vaccine trials: what are the clinical trial site issues? J Int Assoc Physicians AIDS Care. 2005;4:93-97.
5. Stanford PD, Monte DA, Briggs FM, et al. Recruitment and retention of adolescent participants in HIV research: findings from the REACH (reaching for excellence in adolescent care and health) project. J Adolesc Health. 2003;32:192-203.
6. Centers for Disease Control and Prevention (CDC). Fact sheet: young people at risk\-epidemic shifts further toward young women and minorities. Atlanta, GA: The Centers; 1998.
7. Office of National AIDS Policy. Youth and HIV/AIDS 2000: A New American Agenda. Washington, DC: White House; 2000.
8. Mills E, Cooper C, Guyatt G, et al. Barriers to participating in an HIV vaccine trial: a systematic review. AIDS. 2004;18:2235-2242.
9. Fuchs J, Durham M, McLellan-Lemal E, et al. Negative social impacts among volunteers in an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr. 2007;46:362-368.
10. Chesney MA, Chambers DB, Kahn JO. Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr. 1997;16:266-271.
11. Swartz L, Kagee A, Kafaar Z, et al. Social and behavioral aspects of child and adolescent participation in HIV vaccine trials. J Int Assoc Physicians AIDS Care. 2005;4:89-92.
12. Newman PA, Duan N, Lee S, et al. Willingness to participate in HIV vaccine trials: the impact of trial attributes. Prev Med. 2007;44:554-557.
13. Rogers AS. HIV prevention vaccine research in teens: what it will take. Presented at: Adolescent Trials Network/Title IV Youth Services Grantees Joint Meeting; April 14, 2004; Washington, D.C
14. AIDS Vaccine Advocacy Coalition. AIDS Vaccine Trials\-Getting the Global House in Order. New York: AIDS Vaccine Advocacy Coalition; 2004.
15. Valente TW, Vlahov D. Selective risk taking among needle exchange participants: implications for supplemental interventions. Am J Public Health. 2001;91:406-411.
16. Wasserman S, Faust K. Social Networks Analysis: Methods and Applications. Cambridge, United Kingdom: Cambridge University Press; 1994
17. Morris M, ed. Network Epidemiology: A Handbook for Survey Design and Data Collection. New York: Oxford University Press; 2004.
18. Scott J. Network Analysis: A Handbook. 2nd ed. Newbury Park, CA: Sage; 2000.
19. Ellen J, Dolcini M, Bir ND, et al. Social network centrality and sexual experience among a household sample of urban African American adolescents. Connect. 2001;24:76-81.
20. Valente TW. Network Models of the Diffusion of Innovations. Cresskill, NJ: Hampton Press; 1995.
21. Seage GR III, Holte SE, Metzger D, et al. Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol. 2001;153:619-627.
22. Choi K-H, McFarland W, Neilands TB, et al. An opportunity for prevention: prevalence, incidence, and sexual risk for HIV among young Asian and Pacific Islander men who have sex with men, San Francisco. Sex Transm Dis. 2004;31:475-480.
23. MacKellar D, Valleroy L, Karon J, et al. The Young Men's Survey: methods for estimating HIV seroprevalence and risk factors among young men who have sex with men. Public Health Rep. 1996;111:138-144.
24. Bartholow BN, MacQueen KM, Douglas JM Jr, et al. Assessment of the changing willingness to participate in phase III HIV vaccine trials among men who have sex with men. J Acquir Immune Defic Syndr. 1997;16: 108-115.
25. CDC. Update: Syringe Exchange Programs\-United States, 2002. Morb Mortal Wkly Rep (MMWR). 2005;54:673-676.
26. Abdul-Quader AS, Heckathorn DD, Sabin K, et al. Implementation and analysis of respondent driven sampling: lessons learned from the field. J Urban Health. 2006;83:i1-i5.
27. Broadhead RS, Heckathorn DD, Weakliem DL, et al. Harnessing peer networks as an instrument for AIDS prevention: results from a peer-driven intervention. Public Health Rep. 1998;113:42-57.
28. Heckathorn DD. Respondent-driven sampling: a new approach to the study of hidden populations. Soc Prob. 1997;44:174-199.
29. Heckathorn DD. Respondent-driven sampling II: deriving valid population estimates from chain-referral samples of hidden populations. Soc Prob. 2002;49:11-34.
30. Centers for Disease Control and Prevention (CDC). The Handbook for Evaluating HIV Education. Available at: http://www.cdc.gov/Healthy Youth/publications/hiv-handbook/hiv-booklet6/index.htm. Accessed January 22, 2004.
31. Murphy DA, Hoffman D, Seage GR III, et al. Improving comprehension for HIV vaccine trial information among adolescents at risk of HIV. AIDS Care. 2007;19:42-51.
32. Neaigus A, Friedman SR, Curtis R, et al. The relevance of drug injectors' social and risk networks for understanding and preventing HIV infection. Soc Sci Med. 1994;38:67-78.
33. Murray DM, Varnell SP, Blitstein JL. Design and analysis of group-randomized trials: a review of recent methodological developments. Am J Public Health. 2004;94:423-432.
34. Jaspan HB, Cunningham CK, Tucker TJ, et al. Inclusion of adolescents in preventive HIV vaccine trials: public health policy and research design at a crossroads. J Acquir Immune Defic Syndr. 2008;47:86-92.
35. Halpern SD, Metzger DS, Berlin JA, et al. Who will enroll? Predicting participation in a Phase II AIDS vaccine trial. J Acquir Immune Defic Syndr. 2001;27:281-288.
36. Priddy FH, Cheng AC, Salazar LF, et al. Racial and ethnic differences in knowledge and willingness to participate in HIV vaccine trials in an urban population in the Southeastern US. Int J STD AIDS. 2006;17:99-102.
37. Kegeles SM, Johnson MO, Strauss RP, et al. How should HIV vaccine efficacy trials be conducted? Diverse U.S. communities speak out. AIDS Educ Prev. 2006;18:560-572.
38. Koblin BA, Heagerty P, Sheon A, et al. Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States. AIDS. 1998;12:785-793.
39. Marsden PV. Core discussion networks of Americans. Am Sociol Rev. 1987;52:122-131.
40. Hartman RL, Johnson D. Social contagion and multiplexity communication networks as predictors of commitment and role ambiguity. Hum Commun Res. 1989;15:523-548.
41. Haythornthwaite C. Exploring multiplexity: social network structures in a computer-supported distance learning class. Inf Soc. 2001;17:211-226.